March 2015. Volume 11. Number 1

The theoretical cost-effectiveness of the vaccine against group B streptococcus seems high

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Oster G, Edelsberg J, Hennegan K, Lewin C, Narasimhan V, Slobod K, et al. Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective? Vaccine. 2014;32:4778-85.
Reviewers: Ochoa Sangrador C1, Andrés de Llano JM2.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Servicio de Pediatría. Hospital General del Río Carrión. Palencia. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 14/10/2014
Acceptance date: 01/12/2014
Publication date: 11/02/2015

Abstract

Authors´ conclusions: the addition of a trivalent vaccine against group B streptococcus in pregnant women to the current gestational screening programs and intrapartum antibiotics could reduce the burden of disease with cost-effectiveness similar to other vaccines, which have been recently approved in the United States of America.

Reviewers´ commentary: the theoretical cost-effectiveness of a trivalent vaccine against group B streptococcus in pregnant women for the United States of Americais high ($ 91,321 per quality-adjusted life-year gained). However, any decision on the introduction of the vaccine should be subject to verification of their efficacy and safety in clinical trials. The frequency of the disease and the profile of related serotypes in our environment should be also evaluated, because, if there are differences, it would affect the estimates of cost-effectiveness.

How to cite this article

Ochoa Sangrador C, Andrés de Llano JM. El coste-efectividad teórico de la vacuna frente a estreptococo del grupo B parece alto. Evid Pediatr. 2015;11:9.

AVC | Critically appraised articles

Oster G, Edelsberg J, Hennegan K, Lewin C, Narasimhan V, Slobod K, et al. Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective? Vaccine. 2014;32:4778-85.
Reviewers: Ochoa Sangrador C1, Andrés de Llano JM2.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Servicio de Pediatría. Hospital General del Río Carrión. Palencia. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 14/10/2014
Acceptance date: 01/12/2014
Publication date: 11/02/2015

How to cite this article

Ochoa Sangrador C, Andrés de Llano JM. El coste-efectividad teórico de la vacuna frente a estreptococo del grupo B parece alto. Evid Pediatr. 2015;11:9.

References

  1. The UK National Screening Committee policy on Group B Streptococcus screening in pregnancy. [en línea] [consultado el 08/10/2014. Disponible en: http://www.screening.nhs.uk/groupbstreptococcus
  2. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 2002;16:334-43.
  3. Rodríguez Barrios JM, Pérez Alcántara F, Crespo Palomo C, González García P, Antón De Las Heras E, Brosa Riestra M. The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications. Eur J Health Econ. 2012;13:723-40.
  4. Kim SY, Russell LB, Park J, Verani JR, Madhi SA, Cutland CL, et al. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa. Vaccine. 2014;32:1954-63.
11/02/2015

Linked Comment